Alili R. auteur aut IRD Belda E. auteur aut IRD Fabre O. auteur aut IRD Pelloux V. auteur aut IRD Giordano N. auteur aut IRD Legrand R. auteur aut IRD Lassen P. B. auteur aut IRD Swartz T. D. auteur aut IRD Zucker Jean-Daniel auteur aut IRD Clement K. auteur aut IRD text journalArticle eng text/pdf reformatted digital access Background: Dietary intervention is a cornerstone of weight loss therapies. In obesity, a dysbiotic gut microbiota (GM) is characterized by high levels of Bacteroides lineages and low diversity. We examined the GM composition changes, including the Bacteroides 2 enterotype (Bact2), in a real-world weight loss study in subjects following a high-protein hypocaloric diet with or without a live microorganisms (LMP) supplement. Method: 263 volunteers were part of this real-world weight loss program. The first phase was a high-protein low-carbohydrate calorie restriction diet with or without LMP supplements. Fecal samples were obtained at baseline and after 10% weight loss for 163 subjects. Metagenomic profiling was obtained by shotgun sequencing. Results: At baseline, the Bact2 enterotype was more prevalent in subjects with aggravated obesity and metabolic alterations. After weight loss, diversity increased and Bact2 prevalence decreased in subjects with lower GM diversity at baseline, notably in LMP consumers. Significant increases in Akkermansia muciniphila and Parabacteroides distasonis and significant decreases of Eubacterium rectale, Streptococcus thermophilus and Bifidobacterial lineages were observed after weight loss. Conclusions: Baseline microbiome composition is associated with differential changes in GM diversity and Bact2 enterotype prevalence after weight loss. Examining these signatures could drive future personalized nutrition efforts towards more favorable microbiome compositions. specialized obesity gut microbiota weight loss Bacteroides 2 enterotype real-world dietary intervention nanopore technology FRANCE 054 084 10 1 16 [23 p.] 2022 https://www.documentation.ird.fr/hor/fdi:010083967 10.3390/biomedicines10010016 [F B010083967] https://www.documentation.ird.fr/hor/fdi:010083967 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2022-02/010083967.pdf IRD - Base Horizon / Pleins textes 2022-02-04 2025-02-24 fdi:010083967 fre